



# **Patient Reminder Card**

This document has been reviewed and approved by the Saudi Food and Drug Authority (SFDA).

IXIFI 100 mg Infliximah

Patient Name:	Physician Name:		Telephone no.:	
It is important that you and your p	hysician record the brand name and batch	number of your medic	cation.	
Date of IXIFI therapy initiation:	Dates of administration in the current cycle:			
	are you retain this card for reference for fou			-
• Read the IXIFI 'Patient Leaflet'	carefully before you start using this medici	ne.		
	onths after your last dose of IXIFI, or in car		12 months after the birth of your b	abv.
• Side effects may occur after a pr		1 8 37	ŕ	,
	ype and date of the last tuberculosis (TB) s	creening test below:		
Test:	· · · · · · · · · · · · · · · · · · ·	\	Result:	\

#### Infections

# Before using IXIFI

- Tell your physician if you have any infection or get a lot of infections or have infections that keep coming back.1
- It is very important that you tell your physician if you have ever had tuberculosis (TB), or if you have been in close contact with someone with TB. Your physician will test you to see if you have TB. Your doctor should monitor you closely for signs and symptoms of TB during treatment with IXIFL.
- Tell your physician if you have hepatitis B or if you know or suspect that you are a carrier of the virus that causes this disease.
- Tell your physician if you have signs of an infection, such as a fever, cough, flu-like symptoms.1
- Tell your physician if you have any open cuts or sores on your body.1
- Tell your physician if you have diabetes or an immune system problem. People with these conditions have a higher chance for infections.
- Tell your physician if you live or have lived in certain parts of the country (such as the Ohio and Mississippi River valleys) where there is an increased risk for getting certain kinds of fungal infections (histoplasmosis, coccidioidomycosis, or blastomycosis). These infections may develop or become more severe if you receive IXIFI. If you do not know if you have lived in an area where histoplasmosis, coccidioidomycosis, or blastomycosis is common, ask your doctor.1



#### **During Treatment with IXIFI**

• Call your doctor right away if you have an infection, any sign of an infection including a fever, cough, flu-like symptoms, or have open cuts or sores on your body, call your doctor right away.

#### **Heart Problems**

#### Before using IXIFI

• Tell your doctor if you have heart failure or other heart conditions.1

### **During Treatment with IXIFI**

• Tell your doctor of any new or worse symptoms of heart failure including shortness of breath, swelling of ankles or feet, or sudden weight gain.

# **Pregnancy and Vaccinations**

If you received IXIFI while you were pregnant, your baby may have a higher risk for getting an infection.1

If you were receiving IXIFI during your pregnancy, it is crucial to inform your baby's doctor and other healthcare professionals about your IXIFI use. This will help them determine the appropriate timing for your baby's vaccinations.<sup>1</sup>

Your baby must not receive a "live vaccine" such as BCG (intended to prevent tuberculosis) within 12 months after birth. 12

At any visit to a healthcare professional, please make sure to **tell your doctor about all the medicines you take**, including prescription and over-the-counter medicines, vitamins, and herbal supplements.<sup>1</sup>

Keep this card with you for 4 months after receiving the last dose of IXIFI.<sup>1</sup>

# **Reporting of Suspected Adverse Reactions:**

Adverse events can be reported directly to:

The National Pharmacovigilance Center (NPC) at Saudi Food and Drug Authority (SFDA)

SFDA call center: 19999 E-mail: npc.drug@sfda.gov.sa Website: http://ade.sfda.gov.sa

## Pharmacovigilance Department in the Company

E-mail: SAU.AEReporting@pfizer.com

For extra copies, please send an email with your contact details and the required amount to SAU.AEReporting@pfizer.com



Ixifi Package Leaflet. Saudi Arabia, December 2023.
Ixifi LPD. Saudi Arabia, December 2023.



Pfizer Scientific Technical Limited Company: Al Riyadh – Al Aqeek Dis. King Abdullah Financial District, Building 4.07 Postal Code 13519 Tel: +966 12 2293500 Fax: +966 12 2293692

Version Number: 1 Date of Approval: December - 2024.

PP-IFX-SAU-0033